Overview
Didier Serteyn is chief executive of Revatis, based in Liège. He joined Revatis as chief scientific officer in 2014, a role he continues to hold, and became managing director in 2018. Since 2007 he has also been chief scientific officer of Bioptis, and since 2000 a managing partner of the Mont-le-Soie, Equine Research Center.
From October 1995 to October 2024 he was a professor at the University of Liège, holding the qualifications DVM, PhD, Dipl ECVAA and Dipl ECVSMR. He studied veterinary medicine at the University of Liège, completing his degree in 1982.
His stated areas of expertise are creativity and innovation, stem cells, exosomes, regenerative medicine, and research and development.
Career history
In the news
- Cats, dogs and horses are also affected by osteoarthritis Thanks a lot for sharing and supporting the Foundation.
- Revatis strategy in some words! Thanks to BioWin.
- Montons les escaliers ensemble 😉 pour plus de recherches dans ce domaine qui ne touche pas que les humains
- Une belle occasion de rencontrer des jeunes et moins jeunes entrepreneurs et de comprendre les priorités et les stratégies de nos invests publiques. J'ai été interpellé par l'invitation à considérer l'offre chinoise😉 que nous connaissons bien par ailleurs car régulièrement sollicités.
- A new amazing milestone for our Spin-Off company!
- A lot of stem cells products arrive at maturity after more than 10 years of research and development in several fields.
- I am pleased to share that our abstract has been selected for an oral presentation at the 3rd World Congress on Targeting Extracellular Vesicles, to be held on 12–13 November 2026 in Porto, Portugal. "Cytokine priming enhances anti-neutrophil activity of an equine extracellular vesicle-enriched muscle-derived mesenchymal stem cell secretome” This work examines how cytokine priming influences the functional anti-inflammatory activity of an EV-enriched secretome produced from equine muscle-derived mesenchymal stem cells. We look
- We decided some years ago to work in aseptic isolators GMPc for our C&G products in the aim to reduce the COGs and the final prices which must be affordable for patients. Similar views in China but with other financial supports.
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.